<DOC>
	<DOCNO>NCT00028093</DOCNO>
	<brief_summary>This study examine effectiveness pegylated interferon , peginterferon ( long-acting form alpha interferon ) plus ribavirin treating hepatitis C ( genotype 1 ) infection without kidney disease .</brief_summary>
	<brief_title>Pegylated Interferon Ribavirin Treat Chronic Hepatitis C With Without Kidney Disease</brief_title>
	<detailed_description>Up 105 patient chronic hepatitis C enrol study combination pegylated alpha interferon ribavirin 48 week option early discontinuation therapy patient respond within 24 week start therapy . Adult patient choose chronic hepatitis C , HCV RNA serum , HCV genotype 1 liver histology show chronic hepatitis C. Patients advance liver disease clinical decompensation patient receive alpha interferon past eligible . The 100 patient consist four group : Groups A , B D comprise 25 patient typical uncomplicated chronic hepatitis C ; Group C comprise 25 patient renal insufficiency renal failure chronic dialysis await kidney transplantation . Group D comprise 30 patient typical uncomplicated chronic hepatitis C. After medical evaluation liver biopsy , patient begin receive pegylated alpha interferon ( peginterferon ) subcutaneous injection dose 180 mcg per week . After initial injection , patient blood take symptom record 12 , 24 , 48 , 72 hour weekly thereafter four week . Patients Groups A , B C receive peginterferon weekly , whereas patient Group D receive twice weekly reduce dose ( 90 mcg per injection ) first 4 week treatment weekly dose 180 mcg per injection thereafter . Patients Groups A D also begin receive ribavirin orally dose 1000 mg ( body weight less 75 kg ) 1200 mg daily ( body weight great equal 75 kg ) give capsule 200 mg twice daily start first dose peginterferon . Patients Group B start ribavirin dos give first month therapy ( fifth injection : week 4 ) . Patients Group C ( renal disease ) start ribavirin dose 200 mg daily first month ( week 4 ) therapy ; group dose ribavirin gradually increase 4 week interval basis tolerance ( hemolysis anemia ) . During initial 24-week period combination therapy , patient see outpatient clinic medical interview , physical examination blood test 2 4 week interval . At 24 week , patient classify either responder non-responders base upon HCV RNA test . Both group offer therapy another 24 week ( total treatment = 48 week ) . Because sustained response rare patient become HCV RNA negative 24 week , non-responders offer option stop therapy early follow therapy . After stop therapy , patient follow 1 2 month interval undergo repeat medical evaluation ( without liver biopsy ) 72 week point ( 18 month enrollment ) . The primary criterion success therapy overall sustained loss HCV RNA assess 18 month . Secondary criterion normalization ALT level improvement symptom . This study allow therapy patient chronic hepatitis C combination peginterferon ribavirin demonstrate whether early viral kinetics predictive outcome therapy . This study also allow comparison kinetics loss HCV RNA compare peginterferon alone peginterferon ribavirin , peginterferon give weekly peginterferon give twice weekly , compare kinetics patient without renal disease . The study also allow assessment safety addition ribavirin patient renal compromise .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>INCLUSION CRITERIA : All Patients : Age 18 year , male female . Presence HCV RNA ( without antiHCV ) serum . Genotype 1 HCV determine probe specific hybridization ( InnoLipa assay ) . Evidence chronic hepatitis liver biopsy do within previous 48 month necroinflammatory histology activity index least 3 ( maximum 18 ) . Written informed consent . Additional inclusion criterion Groups A , B D : Serum alanine ( ALT ) aspartate aminotransferase ( AST ) upper limit normal range ( ALT 41 great IU/L : AST great 31 IU/L ) serum test previous six month . Additional inclusion criterion Group C : Chronic renal disease creatinine clearance le 50 cc/min serum creatinine great 2.0 mg % . If chronic hemodialysis peritoneal dialysis , stable clinical condition include stable hematocrit . If chronic dialysis , potential candidacy renal transplantation . EXCLUSION CRITERIA : Previous treatment alpha interferon . If cirrhosis present , decompensated liver disease , mark bilirubin great 4 mg % , albumin less 3.0 gm % , prothrombin time great 2 sec prolong , history bleed esophageal varix , ascites hepatic encephalopathy . Serum ALT AST level great 1000 U/L ( great 25 time ULN ) . Such patient enrol may follow three determination level . Pregnancy , woman childbearing potential spouse woman , inability practice adequate contraception , define vasectomy men , tubal ligation woman , use condom spermicide , birth control pill , intrauterine device . Significant systemic major illness renal failure ( Group C ) , include congestive heart failure , organ transplantation , serious psychiatric disease depression , human immunodeficiency virus ( HIV ) infection , angina pectoris . Preexisting anemia ( hematocrit le 33 % ) know history hemolytic anemia . In patient Group C , erythropoetin therapy modify achieve adequate hematocrit clinically indicate . Other antiviral therapy within last 6 month . Immunosuppressive therapy either corticosteroid ( 5 mg prednisone daily ) major immunosuppressive agent ( azathioprine 6mercaptopurine ) . Evidence another form liver disease addition viral hepatitis ( example autoimmune liver disease , Wilson 's disease , alcoholic liver disease , hemochromatosis , alpha1antitrypsin deficiency ) . Evidence coronary artery disease cerebral vascular disease , include abnormality exercise stress test patient define risk factor screen evidence underlie coronary artery disease . Active substance abuse , alcohol , inhale injection drug within previous year . Evidence hepatocellular carcinoma ; either alphafetoprotein ( AFP ) level great 50 ng/ml ( normal less 9 ng/ml ) and/or ultrasound ( image study ) demonstrate mass suggestive liver cancer . Clinical gout . Active , serious autoimmune disease lupus erythematosis , ulcerative colitis , Crohn 's disease rheumatoid arthritis opinion investigator might exacerbate therapy alpha interferon .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Chronic Hepatitis</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Hemolysis</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Alpha Interferon</keyword>
	<keyword>Peginterferon</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Viral Hepatitis</keyword>
	<keyword>Hemolytic Anemia</keyword>
	<keyword>Renal Failure</keyword>
	<keyword>Renal Dialysis</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>